WeVote
Log In

Bill

Bill

S 777

Relates to violations of provisions prohibiting third-party restaurant reservation services from arranging unauthorized restaurant reservations with food service establishments

2025 Regular Session Introduced by George Borrello and 1 co-sponsor

The bill restricts payer mandates on specialty pharmacies, requires safeguards and notice when distributing patient‑specific meds to providers, and ensures safe, timely administrat

SUBSTITUTED BY A843
0
WeVote Research Nonpartisan
Bill Summary · S 777

Summary — S.777 (Senate Docket No. 1222) — "An Act relative to specialty medications and patient safety"

Note: although the metadata in the request contains an unrelated title about restaurant-reservation services, the bill text and docket (S.777 / SD 1222) address specialty medications and patient safety. This summary reflects the bill text.

Purpose

S.777 seeks to protect patient safety and clarify coverage and delivery rules for specialty medications by restricting insurer mandates that force use of third‑party specialty pharmacies in ways that could compromise safe administration. It establishes minimum operational, logistical and notice requirements if payers require specialty pharmacies to supply patient‑specific drugs for administration in provider offices, clinics, or hospitals; and limits payer mandates to use home‑infusion services or third‑party direct‑to‑patient dispensing in certain situations.

Key provisions

  • Definitions: establishes definitions for “specialty pharmacy” and “specialty pharmacy practice” to frame requirements.
  • Prohibitions on payer mandates:
    • The Group Insurance Commission (GIC) may not require a specialty pharmacy to dispense medications directly to patients with the intent that patients transport the drug to a healthcare provider for administration.
    • GIC (and, separately under Chapter 118E, the Medicaid division and contracted plans/ACOs) may offer but may not require use of a home infusion pharmacy or off‑site infusion centers for sterile IV drugs.
  • When payers require distribution of patient‑specific medications from a specialty pharmacy to a provider/hospital/clinic, the bill requires:
    • At least 60 days’ notice to providers and patients before implementation.
    • An expedited exception process when a provider certifies it is unsafe for a patient to receive medication from a third‑party specialty pharmacy or to have home administration.
    • Same‑day delivery; 24/7 on‑call pharmacist or nurse access.
    • Cold‑chain logistics to maintain temperature; pedigree documentation of handling; REMS compliance capability.
    • National accreditation and demonstrated ability to deliver ready‑to‑administer doses at clinically appropriate dosages.
    • Formal agreements between third‑party specialty pharmacies and hospitals receiving medications to ensure proper receipt/handling.
    • Hospital‑owned or affiliated pharmacies may serve as specialty pharmacies for these purposes.
  • Exclusions: payers may not require distribution from specialty pharmacies to provider offices for:
    • Medications requiring sterile compounding by health‑system pharmacy staff.
    • Medications with patient‑specific dosages determined by same‑day lab/test results.
    • Federally controlled substances.
  • Payment: when distribution to a provider is required, payers must offer site‑neutral payment to the administering provider that covers intake, storage and disposal costs.

Who is affected

  • Primary: Group Insurance Commission (state employees/retirees), Massachusetts Medicaid (Chapter 118E) and its contracted plans/ACOs, specialty pharmacies, hospital/health‑system pharmacies, clinicians who administer specialty drugs, home‑infusion providers, and patients receiving specialty therapies.
  • Secondary: third‑party payers, pharmacy accreditation entities, logistics providers.

Procedural status & timeline

  • Filed: Senate Docket No. 1222, filed 1/15/2025; presented by Jason M. Lewis.
  • Introduced: February 27, 2025 (Senate).
  • Committee actions: Referred to Financial Services; hearing scheduled for 06/10/2025 (10:30 AM–1:00 PM) (per docket).
  • Legislative status: Listed as “SUBSTITUTED BY A843” (1/28/2025) — S.777 was replaced by companion/alternate A843; further action may proceed on the substitute.

Potential impacts and considerations

  • Patient safety: strengthens cold‑chain, REMS, and handling safeguards and provides exception paths for clinical safety concerns.
  • Operational/financial: imposes operational requirements on third‑party specialty pharmacies and payment obligations on payers (site‑neutral payments), which could affect costs and contracting arrangements.
  • Care delivery: could shift where specialty drugs are dispensed/administered — toward hospital‑owned pharmacies or retained in clinic compounding — and limit payer ability to mandate third‑party dispensing models.
  • Fiscal impact: bill text does not include cost estimates; implementation could alter payer and provider expenditures.

This summary covers S.777 as submitted; readers should consult the substitute bill A843 (noted in the docket) for the version that may advance.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.